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In this 12-week open-label, uncontrolled study, patients (n = 85; mean [SD] age 11.2 [3.95] years) were trained to use an injection
device with an automatic needle insertion accessory (NordiFlex/NordiFlex PenMate: Novo Nordisk A/S, Bagsvaerd, Denmark) for
growthhormone(GH)injection. Theopinions ofpatients and thephysicians/nurseswho trained patientson device were recorded
by questionnaire. Most (88.4%) patients reported that the device was “very easy/easy” to use. The majority (82.4%) of patients
were “very satisﬁed/satisﬁed” with the device and 64% wished to continue its use. Device training instructions were reported as
“very easy/easy” by 96.1% of physicians/nurses, and 65.8% of participants could use the device after ≤10-minute training. In this
study, NordiFlex PenMate was well accepted by patients and medical staﬀ. Patients had a high opinion of the device and over half
wished to continue its use. High patient acceptance may facilitate treatment adherence optimizing treatment outcomes.
1.Introduction
Since its development in 1985, recombinant human growth
hormone(GH)hasbeenwidelyavailableforthetreatmentin
childhood of many indications, including growth hormone
deﬁciency (GHD), Turner syndrome, chronic renal insuf-
ﬁciency, and short children born small for gestational age
[1]. The majority of patients, especially those treated from
an early age, respond well to treatment, achieving an adult
heightthatiswithinthetargetrange[2,3].Treatmentsuccess
is dependent, however, on full adherence with the prescribed
GHtreatmentregimen.Ifnotwelladheredto,improvements
in linear growth may be impaired [4, 5]. GH products are
administered daily by subcutaneous injection, and this may
be associated with problems of adherence [5]. Given that GH
treatment is administered daily by subcutaneous injection, it
is important that the injection devices used are well accepted
by patients, simple to use, easy to prepare, and simple to
learn. Moreover, since a high proportion of those treated are
young children, the device should be child-friendly and well
accepted by the parents or caregivers who may be respon-
sible for treatment administration. Although the ﬁrst GH
injections were administered using a traditional needle and
syringe, advances in technology have seen the introduction
of devices that vary the method of subcutaneous injection
and the injection product [6].
In subjective evaluations of patient preferences, ease of
use and lack of pain during injections are found to rank2 ISRN Endocrinology
among the top ﬁve device attributes of delivery devices for
administering GH [7, 8]. The appearance or visibility of the
needle is psychologically diﬃcult for many younger patients,
and for this reason they often rely on adults to perform their
injections [9].
Pen injection devices, the current “gold standard” for
injection, are associated with improved convenience and re-
duced pain on injection and allow a larger proportion of
children to inject themselves [6]. Improving the ease of in-
jection and reducing the pain associated with injection has
the potential to increase compliance with therapy [10].
NordiFlex (Novo Nordisk A/S, Bagsvaerd, Denmark) is a
preﬁlled, multidose, disposable pen injection device contain-
ing liquid GH (Norditropin SimpleXx, Novo Nordisk A/S,
Bagsvaerd, Denmark). NordiFlex PenMate is an automatic
needle insertion device, speciﬁcally for use with NordiFlex,
designed to ease injection pain and reduce needle fear. The
NordiFlex PenMatedesign maypositively contributetocom-
pliance [10]. In children with diabetes, use of PenMate with
the insulin injection pen NovoPen (Novo Nordisk A/S, Bags-
vaerd, Denmark) was shown to be associated with lower
perception of pain [11].
In this study, we assessed patient acceptance and com-
pliance with NordiFlex PenMate in usual clinical practice in
children currently on, or starting, GH therapy. Assessment
of patient acceptance was done by questionnaire delivered at
t h ee n do fa1 2 - w e e kp e r i o d .
2. Methods
2.1. Patients. Patients who attended outpatient pediatric
clinics at 16 sites (11 in Germany, four in Sweden, and
one in the Netherlands) between January 2007 and March
2009 who were prescribed NordiFlex in combination with
NordiFlex PenMate as part of usual clinical practice were
eligible for inclusion in the study. Inclusion criteria were
that the patients should be eligible for treatment with Nor-
diFlex in accordance with locally approved labeling. Patients
could be na¨ ıve to GH therapy or currently on GH ther-
apy (excluding NordiFlex) with another GH product but
required switching to a new device. Children with contra-
indications to treatment with Norditropin or who had
previously been treated with NordiFlex were excluded from
the study. Study-speciﬁc written informed consent was ob-
tained in accordance with local guidance. The selection of
patients for inclusion in the study was at the discretion of the
individual treating physicians.
A total of 85 patients (55% boys; Germany, n = 21; The
Netherlands, n = 49; Sweden, n = 15) was included in the
study. Patients (and, if appropriate, their parents or guard-
ians) were given training in the use of NordiFlex with
NordiFlex PenMate. Either the patients or their parents
used the device to administer GH subcutaneously in the
evening. The daily starting dose and frequency, as well as any
change in dose or frequency, were calculated by the treating
physician. Patients were issued with diaries at the ﬁrst visit.
The primary endpoint of the study was the proportion of
patientswhofoundNordiFlexwithNordiFlexPenMate“very
e a s y ”o r“ e a s y ”t ou s ea f t e r1 2w e e k so ft r e a t m e n t .S e c o n d a ry
endpoints included ease of teaching the device, assessed by
nurse questionnaire at the start of the study, patient and par-
ent overall acceptance of the device system and preference
to use NordiFlex with NordiFlex PenMate compared to pre-
v i o u sd e v i c eu s e ,w h e r ea p p r o p r i a t e .
Data were collected at baseline and at the end of the
observation period of 12 weeks (mean 17(±7) weeks) after
treatment start. Baseline assessments included anthropome-
try(height,weight,bodymassindex,andpubertalstatus).At
baseline, the physician or nurse completed a brief question-
naire that assessed training time and ease of training in the
device. At the end of the observation period, at a routine
clinic visit, the physician or responsible study personnel
determined the patients’ and parents’ impressions of the
device using a six-item questionnaire (Figure 1). The ques-
tionnaire was subdivided into two sections on preparation
(ease and time needed to prepare the pen for injection),
plus general questions. In the general section, question 1 as-
sessed the diﬃculty of the injection, question 2 assessed the
patients’ comfort with the injection (depending on whether
theywereself-injectingortheirparents/guardiansperformed
the injection), and question 3 evaluated patient satisfaction.
In question 4, patients were asked if they preferred to use
NordiFlex with or without NordiFlex PenMate and question
5 assessed patients’ comfort with the idea of future use of
NordiFlexPenMate.Question6assessedtechnicaldiﬃculties
with the device during use. Compliance with treatment was
assessed by patient diary. Safety was assessed through the
recording of adverse events.
2.2. Data Analysis. Data are shown for the whole patient
population. Standard descriptive statistics were used. The
primary endpoint was the proportion of subjects who found
NordiFlexwithNorditropinPenMate“veryeasy”or“easy”to
use. The proportion was summarized using frequency count.
Ease of teaching and learning, other acceptability variables,
and compliance to treatment were also assessed using
frequency count. Mean (SD) values were calculated for the
baseline characteristics like patients’ age, height, weight, and
body mass index. As is typical in observational trials using
data from patient questionnaires, data were not available
from all participants for all questions. Furthermore, in some
cases, both the patient and his/her caregiver gave responses
to questions. Since the omission of any data was assumed to
be random, there was no input for missing data and all
responses have been reported. Thus, for each question, the
base population is dependent on the number of question-
naires returned with an answer for that particular question.
3. Results
Patient demographic characteristics at baseline are shown in
Table 1.Mean(SD)ageinchildrenwhoself-injectedwas13.7
(2.2) years, which was older than the mean age for patients
whose parents performed the injection (9.0 (3.8) years) and
for those where injections were performed by both patients
andtheirparents(10.3(3.2)years).Ofpatients(n = 66)who
switchedfromotherGHinjectiondevices,10(15%)changed
device due to fears/anxieties associated with needles orISRN Endocrinology 3
Preparation
Very easy Easy Very
Longer than 30minutes
General questions
Very easy Easy
Did you have pain or discomfort during
injection with your current injection system?
Did you experience fears/anxiety because of
needle/injection?
Did you sometimes get annoyed or angry
because of your treatment?
Did the need for injections limit your activities?
?
∗Please give a comment in case you answered with “Very” or “Extremely”
Did your child have pain or discomfort during
injection with your current injection system?
Did your child experience fears/anxiety
because of needle/injection?
Did your child sometimes get annoyed or angry
because of your treatment?
(1) Think about all the handling procedures applicable for
before making the injection. Did you ﬁnd the preparation easy/
(2) All together, how long did it approximately take you to prepare the device at home?
(1)Overall,howeasy/ wasittoinjectgrowthhormoneusing
(2a) (If child has done injections by him-/herself)
During the last4weeks of injections using
(2b) (If parent has done injections)
During the last4weeks of injections using
difﬁcult?
Difﬁcult
Difﬁcult
difﬁcult
Very difﬁcult
difﬁcult
NordiFlex with
NordiFlex with
Did you have any using NordiFlex
NordiFlex
difﬁculties
PenMate device
PenMate?
with NordiFlex NordiFlex PenMate
with NordiFlex NordiFlex PenMate
Did the need for injections limit activities of
your child?
∗Please give a comment in case you answered with “Very” or “Extremely”
N o ta ta ll
N o ta ta ll
A little
A little
Very
Very
Extremely
Extremely
Did you have any using difﬁculties
NordiFlex
NordiFlex
with NordiFlex PenMate ∗
? PenMate ∗
1–2minutes 3–5minutes 6–10minutes 11–15minutes
16–30minutes
Figure 1: Continued.4 ISRN Endocrinology
(3)Howsatisﬁedareyouoverallusing
Very satisﬁed Satisﬁed Rather unsatisﬁed Not satisﬁed at all
(4) Did you use
Always Seldom∗ Only at treatment start∗ N o ta ta l l ∗
∗If you ticked “Seldom”, “Only at treatment start” or “Not at all”, please notify a reason for this
(5) Which system will you prefer for continuation of growth hormone treatment?
Previous system (for patients who were switched from another preparation)∗
None of them∗
∗Please refer to the next question “6”
(6) In case of therapy discontinuation
(multiple choice is possible)
Pain or discomfort during injections with this system
Fears/anxiety because of needle/injection
Lack of compliance or motivation
Limitations of every day activities with the system
to use the system
Stop of growth hormone therapy in general
Non-fulﬁlled treatment expectations
Other reasons
If other reasons, please give a comment
Difﬁculties
with NordiFlex NordiFlex
NordiFlex combination with NordiFlex
NordiFlex with NordiFlex
NordiFlex without NordiFlex
with NordiFlex or NordiFlex PenMate please note the reason/s
PenMate?
PenMate?
PenMate
PenMate∗
By ﬁlling in this ﬁeld please consider whether Adverse Event or Device Adverse
completed
Effects Forms should be
Figure 1: Questionnaire used to assess patients’ acceptance of the Norditropin NordiFlex pen and NordiFlex PenMate in pediatric patients
treated with growth hormone.
the injection process, one patient due to lack of compliance,
and another due to diﬃculties with their existing device. No
reason was given for other patients switching to NordiFlex.
Atotalof12patientsdiscontinuedtreatmentwithNordi-
Flex PenMate during the observation period. Reasons given
for discontinuation were as follows: four (5%) stopped due
to pain or discomfort, three (4%) because of diﬃculties with
device use, two (2.5%) because they had ﬁnished treatment
with GH, two (2.5%) due to “other” reasons, and one (1%)
patient each because of lack of compliance, fears/anxieties,
limitations, and nonfulﬁlled expectations (note that one pa-
tient reported three reasons and another gave two reasons).
Overall, 79-patient questionnaires were completed and re-
turned for analysis and 22-patient diaries (10 ﬁlled out by
children, 12 completed by parents) were completed and re-
turned.
3.1. Eﬃcacy Evaluation. During the observation period,
88.4% (61/69) of children reported that treatment with Nor-
diFlex PenMate was “very easy” or “easy” (Figure 2). Few
patients(11.6%,8/69)reportedthattheinjectionprocesswas
“diﬃcult” or “very diﬃcult”. “No diﬃculties” with the injec-
tion process were reported by 90% (27/30) of children who
self-injected, by 88.5% (23/26) of caregivers who performedISRN Endocrinology 5
Table 1: Patient demographic characteristics at baseline.
Characteristic
Age (years), mean (SD) 11.27 ±3.95
Sex (male/female), % 47/38 (55.4/44.6)
Height (cm), mean (SD) 139.5 (29.3)
Weight (kg), mean (SD) 36.3 (18.3)
Body mass index (kg/m2), mean (SD) 12.4 (4.9)
Diagnosis (n), (%)
GHD 28 (32.9%)
Acquired GHD 9 (10.6%)
SGA 23 (27.0%)
Turner syndrome 11 (12.9%)
“Other” 14 (16.5%)
Previous GH therapy (n), (%)
GH-na¨ ıve 19 (22.4%)
Switched from another GH device 66 (77.6%)
GH: growth hormone; GHD: growth hormone deﬁciency; SD: standard
deviation; SGA: small for gestational age.
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Figure 2: Patients’ assessment of treatment with NordiFlex with
NordiFlex PenMate at the end of the observation period (mean
17 ±7w e e k s )( n = 79).
the injections, and by 83.4% (10/12) of patients who were
injected by themselves or their caregivers. Patients na¨ ıve to
GH treatment (n = 16) rated the easiness of injections
even more positively than those on established treatment
regimens, with 93.8% (15/16) rating the injection process
“easy” or “very easy”.
Patients’ overall impression of the device was good, with
the majority of patients (82.4%, 56/68) reporting that they
were “satisﬁed” or “very satisﬁed” with the device; only
5.9% (4/68) were “not satisﬁed”. All treatment-na¨ ıve patients
reported that they were “satisﬁed” or “very satisﬁed”. For
caregivers who injected children, 86% (24/28) reported satis-
faction with the device, while 82.1% (23/28) of children who
self-injected stated that they were “satisﬁed” with the device.
In families where both patients and caregivers performed
injections, 75% (9/12) were satisﬁed with treatment. All
patients who reported that they were “rather unsatisﬁed” or
“not satisﬁed” with the device (n = 12) had been switched
from other devices.
Over half of respondents (64%, 46/72) reported that they
would prefer to use NordiFlex PenMate for future GH de-
livery. Of the remaining patients, 18% (13/72) reported that
they would like to use NordiFlex without PenMate in the
future,whileasimilarproportion(18%)preferredtheirorig-
inaldeviceoverNordiFlexPenMate.Preferenceforfutureuse
of NordiFlex PenMate was especially high in patients who
were treatment-na¨ ıve (80%) and in caregivers who per-
formed the injections (74.1%).
Almost all patients (97.4%, 75/77) found preparation of
NordiFlex PenMate for injection “very easy” or “easy”, with
onlytwopatientsstatingthattheyfoundtheprocessdiﬃcult.
In almost two-thirds of patients (62.2%, 46/74) the injection
preparationtimewaslessthan2minutes,anditwaslessthan
5minutes forallbuttwooftheremainingpatients. Thelatter
two patients were able to prepare the device for injection in
less than 10 minutes.
Most patients reported very little pain on injection and
little fear or anxiety with the injection process (Figure 3).
The use of the device was not considered to have a sig-
nificant adverse eﬀect on patients’ activities or to cause any
annoyance or irritation due to its use. Although the ratings
were generally not that diﬀerent when injections were
performedbythechildorbythecaregiver,patientsidentiﬁed
slightly more anxiety and pain or discomfort when the
injections were not given by themselves.
Data from the returned patient diaries (12 completed
by caregivers and 10 completed by self-injecting children)
indicated that overall compliance was good in the observed
cohort. Among children who self-injected, on average,
3.4 injections/child were missed during the observation
period, and among caregivers, there was an average of 2.1
injections/patient missed during this period. None of the
injectionsweremissedduetofear/anxietyabouttheinjection
process; most were missed as they were either forgotten, the
device was not available at the time of injection, or for other
reasons.
3.2. Nurses, and Physicians’ Opinions of Device Training.
Instruction in device use was given to 30 caregivers, 15
patients and 38 patients in association with caregivers. The
majority of physicians (96.1%) who trained participants in
the use of the device reported that the device instructions
were “very easy” or “easy”. Initial training in the device took
6–10 minutes for 40.2% (33/82) of patients or their care-
givers and 3–5 minutes for 25.6% (21/82) of patients or care-
givers. Overall, only 31.7% of patients required 10 minutes
or more of initial training. For patients switching from other
devices, 87.5% required 10 minutes or less of instruction.
3.3. Safety Results. One child had a rash (nonserious adverse
drug reaction) and three reported technical complaints
(needle placement (two reports) and uncertainty about the
correct dosing (one report)) during the observation period.
4. Discussion
In the current study, patients and, where appropriate, their
caregivers, as well as the nurses who provided training, had6 ISRN Endocrinology
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Figure 3: Patients’ rating of the injection process using NordiFlex with NordiFlex PenMate, rated according to whether the injection was
performed by the child (self-injection) (n = 39) or by his/her caregiver (n = 40). In both groups, a small number of families gave responses
from both the child and caregiver; therefore, a minor overlap in responses was observed.
a high opinion of NordiFlex PenMate. After the observation
period, almost 90% of patients reported that injection of
GH using NordiFlex PenMate was “very easy” or “easy”; few
patients reported any diﬃculties using the device. In line
with these observations, high patient satisfaction with the
device was reported by both children who self-injected and
children who had their injections given by caregivers. It is
noteworthy that treatment satisfaction was especially high
among treatment-na¨ ıve patients. Indeed, after the observa-
tion period, most patients (80%) stated that they would like
to continue using the device in the future.
Patients and their caregivers quickly learned to use the
device and found the injection process easy to learn. Initial
trainingwascompletedinlessthan10minutesfortwo-thirds
of patients and caregivers. Training time was further reduced
in patients switching from other devices. Almost all of the
physicians who provided training found the instructions for
use “very easy” or “easy” to deliver. In support of these ﬁnd-
ings was the observation that half of the patients were able
to self-inject without assistance. Ease of use is recognized
as a key factor in device acceptance [8] and is especially
important when the device is to be used by a child or
adolescent. Key factors in ease of use are the number of steps
in device preparation (the fewer the better) and ease of dose
setting. In the present study, more than half of the patients
were able to prepare the device for injection in less than 2
minutes and almost all patients found the device “easy” or
“very easy” to prepare for use. Ease of use might also increase
thenumberofpatientswhoself-inject,whichhasbeenfound
to have a positive eﬀect on treatment adherence [12]. In a
multicenter questionnaire survey involving patients and/or
their relatives who had been on GH treatment for more than
6 months, patients who self-injected GH were reported to
have a signiﬁcantly higher rate of adherence than those who
had the injection administered by a parent, guardian, or
healthcare professional (P<0.01) [12].
Pain and perceived pain associated with injection may
directly aﬀect the patient’s adherence and acceptance of
treatment; hence, it is important to minimize pain associated
with the injection process. Both injection technique and
needle quality may inﬂuence injection pain [13]. Reduced
needle diameter has been shown to have a marked impact
on the reduction of injection pain [14], and previous studies
have shown that patients prefer autoinjection over manual
insertion of a needle [15, 16]. A key aim of the NordiFlex
PenMate design is to make the injection process as easy
and painless as possible. In 57 patients with diabetes, the
use of NordiFlex PenMate was associated with a signiﬁcant
(P<0.0 5 )r e d u c t i o ni np a i no ni n j e c t i o n[ 11]. In the present
study, a lack of pain with injection was reported by 71.7%
of patients who self-injected and by 60% of those whose
injections were given by their parents. Overall, only four
patients stated that they experienced signiﬁcant pain on
injection.ISRN Endocrinology 7
While the experience of pain undoubtedly has a signif-
icant impact on patients’ experience with a GH injection
device, the ability to carry out activities of daily life without
interference from therapy could also inﬂuence their impres-
sion of the device. When asked to consider factors such as
discomfort, anxiety, annoyance or anger, and feelings of
being limited in activities, most patients responded posi-
tively, indicating that they considered the device to have little
impact on their activities of daily living.
Growth velocity is directly inﬂuenced by both the dose of
GH and the frequency of injection [3]. Children with poor
adherence have signiﬁcantly reduced growth rates compared
to those who receive a higher proportion of their prescribed
dose [4, 17]. A questionnaire study of 75 GH-deﬁcient
children revealed that missing two or more injections per
week was associated with a 42% reduction in growth velocity
compared with children who received all their weekly
injections (4.6cm/year versus 7.8cm/year; P<0.05). In that
study, 39% missed more than one injection per week and
23% missed more than two injections per week [17]. These
proportions are consistent with other studies using objective
assessments. Hunter et al. found that 33% of patients (<18
years) received less than 80% of the prescribed GH dose
[18],andthatadherencewaspositivelycorrelatedwithheight
standard deviation score (SDS) (P<0.001). Similarly, Des-
rosiers et al. reported that 9.5% (58/609) of patients on
GH therapy missed more than half (>15) of their monthly
injections [4]. Twelve-month height-velocity data in patients
missing >15 injections/month (6.3cm/year) was only 67%
of the height velocity achieved by patients missing 11–15
doses/month (9.4cm/year) (P ≤ 0.03). In the present study,
reported overall compliance with treatment was good, with
few injections missed. Care should be taken in interpreting
these data, as not all patient diaries, which were used as the
source of compliance data in the study, were returned for
assessment.
The high patient acceptance of the device in this study, as
wellaseaseofuse,werealignedwithafavorablesafetyproﬁle
and low reporting of technical complaints. Notably, patient
satisfaction was particularly high among patients na¨ ıve to
GH therapy. These patients also gave a positive assessment
of the ease of injection and stated that they would like to
continue use of the device in the future. Patient satisfaction
with his/her GH device has been positively associated with
adherence. In a study of 75 GH-deﬁcient children, of a sim-
ilar age (median (interquartile range) 12.3 (8.9t o1 4 .8)
years)tothoseincluded inthepresentstudy,lackofchoiceof
GH device was signiﬁcantly (P<0.05) associated with lower
treatmentconcordance[17].Inanearlierstudy,concordance
was reported to be unaﬀected by the choice of GH device
[19]. In that study, following a change in clinic policy that
allowed patients a free choice of GH device, there was no
change in concordance with GH therapy. It should be noted,
however,thatconcordancewithGHtherapywasalreadyhigh
at the clinic (87%). Interestingly, patients oﬀered free choice
of device cited better satisfaction with their treatment.
The current study was designed to evaluate patient’s
acceptance and satisfaction with NordiFlex and NordiFlex
PenMate as well as to examine patient compliance with
the device based on information recorded in patient diaries.
No comparator devices were assessed directly; however,
manypatientshadswitchedfromotherdevicesandtherefore
were able to indirectly compare their experiences with use of
other pen devices. Analyses were made on a number of sub-
groupsfromwithinthepatientpopulation,forexample,self-
injectors versus those injected by parents/carers; treatment-
naive versus nonnaive patients, to better understand the
needs of diﬀerent sectors of the patient population, and the
beneﬁts of the device and its accessory for these patients.
In summary, in this study of patients injecting GH using
NordiFlex PenMate, patients reported a good overall impres-
sion of the device, with patients and caregivers quickly learn-
ing to use the device, and the majority expressing a strong
preference to continue using the device in the future. Physi-
cians and nurses involved in training patients and caregivers
in use of the device similarly considered the device to be easy
to learn and to teach. Together, these ﬁndings support that
NordiFlex PenMate is a well-accepted, preferred option for
patients receiving daily subcutaneous injections of GH.
The features of NordiFlex PenMate may simplify the
injectionprocess,helpreducepainperception,and,withthis,
facilitate patients’ adherence to the regimen of daily injec-
tions, in turn improving their outcomes from GH therapy.
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